Edesa Biotech (EDSA) Competitors $2.34 +0.08 (+3.54%) As of 04/16/2025 03:59 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock EDSA vs. ACHL, ANRO, ZIVO, SCLX, BDRX, IOBT, INCR, SGMT, VTYX, and LXEOShould you be buying Edesa Biotech stock or one of its competitors? The main competitors of Edesa Biotech include Achilles Therapeutics (ACHL), Alto Neuroscience (ANRO), ZIVO Bioscience (ZIVO), Scilex (SCLX), Biodexa Pharmaceuticals (BDRX), IO Biotech (IOBT), InterCure (INCR), Sagimet Biosciences (SGMT), Ventyx Biosciences (VTYX), and Lexeo Therapeutics (LXEO). These companies are all part of the "pharmaceutical products" industry. Edesa Biotech vs. Achilles Therapeutics Alto Neuroscience ZIVO Bioscience Scilex Biodexa Pharmaceuticals IO Biotech InterCure Sagimet Biosciences Ventyx Biosciences Lexeo Therapeutics Achilles Therapeutics (NASDAQ:ACHL) and Edesa Biotech (NASDAQ:EDSA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, profitability, community ranking, valuation, risk, dividends, media sentiment and earnings. Is ACHL or EDSA more profitable? Achilles Therapeutics' return on equity of -54.45% beat Edesa Biotech's return on equity.Company Net Margins Return on Equity Return on Assets Achilles TherapeuticsN/A -54.45% -47.68% Edesa Biotech N/A -233.69%-124.14% Which has more risk & volatility, ACHL or EDSA? Achilles Therapeutics has a beta of 1.25, meaning that its share price is 25% more volatile than the S&P 500. Comparatively, Edesa Biotech has a beta of 0.6, meaning that its share price is 40% less volatile than the S&P 500. Do insiders and institutionals hold more shares of ACHL or EDSA? 56.4% of Achilles Therapeutics shares are held by institutional investors. Comparatively, 5.5% of Edesa Biotech shares are held by institutional investors. 5.4% of Achilles Therapeutics shares are held by insiders. Comparatively, 25.0% of Edesa Biotech shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Does the MarketBeat Community favor ACHL or EDSA? Edesa Biotech received 11 more outperform votes than Achilles Therapeutics when rated by MarketBeat users. Likewise, 77.78% of users gave Edesa Biotech an outperform vote while only 54.84% of users gave Achilles Therapeutics an outperform vote. CompanyUnderperformOutperformAchilles TherapeuticsOutperform Votes1754.84% Underperform Votes1445.16% Edesa BiotechOutperform Votes2877.78% Underperform Votes822.22% Which has preferable earnings & valuation, ACHL or EDSA? Edesa Biotech is trading at a lower price-to-earnings ratio than Achilles Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAchilles TherapeuticsN/AN/A-$69.67M-$1.65-0.90Edesa BiotechN/AN/A-$6.17M-$1.87-1.25 Does the media refer more to ACHL or EDSA? In the previous week, Edesa Biotech had 1 more articles in the media than Achilles Therapeutics. MarketBeat recorded 1 mentions for Edesa Biotech and 0 mentions for Achilles Therapeutics. Edesa Biotech's average media sentiment score of 1.44 beat Achilles Therapeutics' score of 0.00 indicating that Edesa Biotech is being referred to more favorably in the news media. Company Overall Sentiment Achilles Therapeutics Neutral Edesa Biotech Positive Do analysts recommend ACHL or EDSA? Edesa Biotech has a consensus target price of $21.00, indicating a potential upside of 797.44%. Given Edesa Biotech's stronger consensus rating and higher probable upside, analysts plainly believe Edesa Biotech is more favorable than Achilles Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Achilles Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Edesa Biotech 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryEdesa Biotech beats Achilles Therapeutics on 9 of the 15 factors compared between the two stocks. Remove Ads Get Edesa Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for EDSA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EDSA vs. The Competition Export to ExcelMetricEdesa BiotechPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$16.36M$6.25B$5.28B$7.36BDividend YieldN/A3.24%5.11%4.32%P/E Ratio-1.256.6921.6317.68Price / SalesN/A222.70371.0892.88Price / CashN/A65.6738.1534.64Price / Book13.005.776.373.94Net Income-$6.17M$142.01M$3.20B$247.45M7 Day Performance4.93%2.88%1.79%0.48%1 Month Performance-2.09%-13.93%-9.41%-7.08%1 Year Performance-46.15%-12.36%9.61%-0.35% Edesa Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EDSAEdesa Biotech3.262 of 5 stars$2.34+3.5%$21.00+797.4%-46.2%$16.36MN/A-1.2520Short Interest ↓Positive NewsACHLAchilles TherapeuticsN/A$1.48flatN/AN/A$60.83MN/A-0.90250ANROAlto Neuroscience1.6576 of 5 stars$2.25+24.8%$15.40+585.7%-83.5%$60.80MN/A-0.88N/AGap UpHigh Trading VolumeZIVOZIVO BioscienceN/A$16.00+1.5%N/A+120.1%$60.66M$15,850.00-3.2810SCLXScilex2.0927 of 5 stars$0.25-3.7%$13.00+5,131.4%-84.9%$60.46M$56.59M-0.3080Stock SplitNews CoverageGap DownBDRXBiodexa Pharmaceuticals0.6875 of 5 stars$1.65-2.4%N/AN/A$60.30M$83,000.000.0020Gap DownIOBTIO Biotech2.8894 of 5 stars$0.91-7.5%$9.33+925.6%-42.2%$59.95MN/A-0.6630Short Interest ↑Gap UpINCRInterCure0.5456 of 5 stars$1.31+2.3%N/A-42.4%$59.70M$272.67M0.00350Short Interest ↑News CoverageGap UpSGMTSagimet Biosciences2.6919 of 5 stars$1.94-6.7%$22.40+1,054.6%-51.7%$59.51M$2M-1.368News CoverageVTYXVentyx Biosciences2.1045 of 5 stars$0.84-11.0%$10.00+1,096.0%-77.7%$59.47MN/A-0.3530Positive NewsHigh Trading VolumeLXEOLexeo Therapeutics2.8654 of 5 stars$1.79-23.5%$22.80+1,173.7%-81.4%$59.42M$650,000.00-0.5758High Trading Volume Remove Ads Related Companies and Tools Related Companies ACHL Competitors ANRO Competitors ZIVO Competitors SCLX Competitors BDRX Competitors IOBT Competitors INCR Competitors SGMT Competitors VTYX Competitors LXEO Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EDSA) was last updated on 4/17/2025 by MarketBeat.com Staff From Our Partners[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Edesa Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Edesa Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
